FDA will survey how visuals distract viewers

Share this article:
The FDA will test broadcast-style ads for a bogus blood pressure drug as part of a survey aimed at determining how visuals may distract viewers from risk information. The survey of 2,400 consumers—ages 40 and up—will feature several executions of the bogus ads to evaluate recall and comprehension of risk information. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M inVISION